Steve Sanford, MD in Willoughby, OH - Preventive Medicine

Steve Sanford, MD is a Preventive Medicine - Occupational Medicine physician based in Willoughby, Ohio. Steve Sanford is licensed to practice in Ohio (license number 35.052005) and his current practice location is 3900 Ben Hur Ave, Willoughby, Ohio. He can be reached at his office (for appointments etc.) via phone at (440) 975-4185.

NPI number for Steve Sanford is 1033203351 and his current mailing address is 3900 Ben Hur Ave, Willoughby, Ohio. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1033203351.

Contact Information

	Steve Sanford, MD
	3900 Ben Hur Ave, Willoughby, OH 44094-6398
	(440) 975-4185
	(440) 975-4195

Physician's Profile

Full Name	Steve Sanford
Gender	Male
Speciality	Preventive Medicine - Occupational Medicine
Location	3900 Ben Hur Ave, Willoughby, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1033203351
Provider Enumeration Date: 10/03/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Steve Sanford such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1033203351	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2083X0100X	Preventive Medicine - Occupational Medicine	35.052005 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Steve Sanford is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Steve Sanford, MD 3900 Ben Hur Ave, Willoughby, OH 44094-6398 Ph: (440) 975-4185	Steve Sanford, MD 3900 Ben Hur Ave, Willoughby, OH 44094-6398 Ph: (440) 975-4185

News Archive

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.

Washington Post examines development of vaccine for food borne intestinal illness

The Partnership for Public Service/Washington Post examines how decades of work by Navy scientist Patricia Guerry could lead to "the first vaccine for a food borne intestinal illness that affects hundreds of millions of people worldwide each year."

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

New $3.2 million NIH grant funds development of mobile Critical Care Recovery Program

Two million of the five million Americans admitted to intensive care units annually have or develop acute respiratory failure, predisposing them to long-term cognitive, functional and psychological impairments collectively known as post-intensive care syndrome.

Four commonly used medications to treat pregnant women with migraines may not be safe

According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be.

Steve Sanford, MD - Preventive Medicine in Willoughby, OH